News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow by Adam Sheldon April 20, 2026April 22, 2026 Nexalis Therapeutics – formerly InhaleRx – has completed dosing in the first cohort of its Phase […]
Financial news in brief: Elixinol addresses funding concerns; Aurora growth helped by Australia; Avecho lifts cash, progresses trial; Cann receives NAB extension to finalise settlement; IRX reports lean quarter by Adam Sheldon November 4, 2025February 21, 2026
Cannabis executive salaries: who earned what in FY25 by Adam Sheldon October 22, 2025October 22, 2025
Elixinol Wellness secures A$2.5m to fund ‘reset strategy’ by Adam Sheldon September 8, 2025February 21, 2026
News in brief: Losses widen for Avecho and Elixinol; InhaleRx secures HREC approval; Zelira cuts deficit; Argent shifts from ‘non-core’ activities by Adam Sheldon August 29, 2025February 21, 2026
Financial news in brief: Elixinol reassures ASX over financing; NTI shuts down two subsidiaries by Steve Jones August 1, 2025August 1, 2025
Financial news in brief: Ecofibre looks to sell Ananda Health; product delays hit Elixinol by Steve Jones April 30, 2025April 30, 2025
Financial results: Elixinol Wellness; Rua Bioscience; Wellnex Life by Steve Jones March 3, 2025March 5, 2025
Company news: Bioxyne/BLS; Wellnex Life; Elixinol Wellness; Althea; Health House; Rua Bioscience by Steve Jones and Martin Lane February 7, 2024November 25, 2024
